Aztreonam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Aztreonam
- Pharmacist Assessment Report
- Aztreonam: Monobactam antibiotic → polyclonal hyperviscosity syndrome (polyclonal hyperviscosity syndrome)
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Aztreonam: Monobactam antibiotic → polyclonal hyperviscosity syndrome (polyclonal hyperviscosity syndrome)
One-Sentence Summary
Aztreonam is a monobactam antibiotic that acts against aerobic Gram-negative bacteria and is marketed in Canada. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome (polyclonal hyperviscosity syndrome), but no clinical trials and no publications support this prediction, and no plausible mechanistic link was identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | polyclonal hyperviscosity syndrome (polyclonal hyperviscosity syndrome) |
| TxGNN Prediction Score | 0.9973 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Aztreonam is generally known as a monobactam that inhibits penicillin-binding protein 3 in aerobic Gram-negative bacteria, which is an antibacterial action.
Polyclonal hyperviscosity syndrome is a protein/immunoglobulin disorder rather than an infection. No plausible mechanistic link to aztreonam’s antibacterial activity was identified. The high TxGNN score appears to be a model artifact rather than a signal supported by clinical or literature evidence, so the prediction should be treated with strong caution.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02329840 | CAYSTON | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 27 potential interactions were identified in the interaction databases. Those with a Moderate level include picosulfuric acid, dicoumarol and warfarin (anticoagulant effect should be monitored when combined). Others, such as vancomycin, amikacin, amphotericin B, tacrolimus, heparin and acetylsalicylic acid, have no rated severity.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or publications, and aztreonam’s antibacterial mechanism has no recognized relationship to polyclonal hyperviscosity syndrome. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Any clinical or preclinical evidence that directly studies this disease with aztreonam
- A plausible mechanistic rationale
- Health Canada package insert warnings and contraindications for safety screening
- Detailed mechanism of action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.